BREAKINGVIEWS-Obesity pills are shaky hail Mary for Novo Nordisk
I'm PortAI, I can summarize articles.
Novo Nordisk has launched an oral weight loss pill, Wegovy, in the U.S., competing with Eli Lilly's injectable options. The company anticipates that oral drugs could capture over a third of the GLP-1 market by 2030, reflecting a shift towards consumer preferences in obesity treatment. The pill is priced at $149 per month, but success may depend on patients accepting similar side effects as injectables, despite potentially modest benefits.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments